clonoSEQ is now covered by Medicare for MCL patients.
It is the first Medicare-reimbursed MRD test for patients with MCL and is clinically available as a CLIA-validated LDT.
For more information about incorporating clonoSEQ into your clinical practice for MCL patients, click here.
Electronic Medical Records (EMR) Integration
Integrating clonoSEQ ordering and reporting
Adaptive EMR integration streamlines workflows so healthcare providers can focus on delivering better care. With integration available for most major platforms, Adaptive makes it easier to place orders, reduce manual entry errors, and access results in the patient’s chart. Diagnostic insights are available alongside treatment plans, improving clinical workflows and supporting more informed decision-making.
For Patients
Share test results directly via your EMR portal, with integrated results available sooner.
For Clinics
Save time and improve order accuracy. Providers can electronically order clonoSEQ and view results directly in their EMR workflow.
For Laboratories
Quicker turnaround times and a more efficient pathology workflow. EMR integration with Adaptive reduces administrative overhead.
Data Accessibility
Adaptive is committed to ensuring critical information for patient care is available to support better informed decision making.
All results are sent to the Health Information Exchanges (HIEs), such as Epic’s Care Everywhere and Carequality.
40+ direct data connections across 200+ healthcare institutions
- Epic customers can easily integrate clonoSEQ orders and results within existing workflows
- 8-12 week integration, supported with a clear project plan and an experienced Adaptive project team
- All results are sent to Epic’s Care Everywhere network and Carequality, ensuring critical information for patient care is available for efficient decision making
- OncoEMR customers utilizing Molecular Profiling Integration (MPI) can instantly access the integrated clonoSEQ order with no additional implementation time
- The clonoSEQ MPI order offers customized serial testing to best support clinical care goals
Interested in clonoSEQ EMR Integration?
Connect with an Integration Expert for more information: emrsupport@adaptivebiotech.com
Regardless of vendor, Adaptive can provide clonoSEQ EMR integration support.
Resources:
For Additional Support:
Adaptive Clinical Services Team
Call 1-888-552-8988, opt. 1 from 5:30 am to 5 pm PT, Monday through Friday, or email clinicalservices@adaptivebiotech.com.
Laboratory Shipping Address
Adaptive Biotechnologies
Attention: CLIA Clinical Laboratory
1165 Eastlake Avenue E
Seattle, WA 98109
Intake Hours
Monday–Saturday
8 am to 5 pm PT
Laboratory Licenses
View our CAP accreditation and our CLIA license.
Biological specimens can be received and accessioned on the days and times above.
Epic, Aura, and Care Everywhere are trademarks of Epic Systems Corporation.
OncoEMR® is a registered trademark of Flatiron Health.
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.